Global Nucleic Acid-Based Therapeutics Market, By Application Monogenic Disorders and Multigenic Disorders, Structure (Single Stranded RNA/DNA, Double Stranded DNA), Technologies (Anti-Sense Technology, Gene Therapy, RNA and DNA Therapy, Aptamers, Nucleoside Analogs, and Others), End-Users (Hospitals, Research Institutes, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) – Industry Trends and Forecast to 2030.
Nucleic Acid-Based Therapeutics Market Analysis and Size
Novel treatment techniques based on nucleic acid medicines are being developed. Due to unique properties that allow them to address undruggable targets using traditional small molecule or protein/antibody-based biologics, they promise in treating human diseases such as malignancies, viral infections, and genetic abnormalities. Nucleic acid medications use nucleotide sequence information to influence the biological processes of cells. These medications act either because of their expression in cells or because of the control of genes, particularly those with complementary sequences.
Data Bridge Market Research analyses that the global nucleic acid-based therapeutics market which was USD 3783.72 million in 2022, would rocket up to USD 12466.57 million by 2030, and is expected to undergo a CAGR of 14.29% during the forecast period. This indicates that the market value. of “antisense technology” is expected to dominate the technology segment of the global nucleic acid-based therapeutics market owing to the rise in technological advancement. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Nucleic Acid-Based Therapeutics Market Scope and Segmentation
2023 to 2030
2021 (Customizable to 2015-2020)
Revenue in USD Million, Volumes in Units, Pricing in USD
Application (Monogenic Disorders and Multigenic Disorders, Structure (Single Stranded RNA/DNA, Double Stranded DNA), Technologies (Anti-Sense Technology, Gene Therapy, RNA and DNA Therapy, Aptamers, Nucleoside Analogs, and Others), End-Users (Hospitals, Research Institutes, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others),
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Market Players Covered
Wave Life Sciences Ltd. (US), Copernicus Therapeutics Inc. (US), Imugene (Australia), PYC Therapeutics (Australia), Protagonist Therapeutics Inc. (US), Benitec Biopharma (Australia), Egen, Inc. (US), Biomedica Medizinprodukte GmbH (UK), Transgene (France), Arrowhead Pharmaceuticals, Inc. (US), Ionis Pharmaceuticals (US), Alnylam Pharmaceuticals, Inc. (US), Moderna, Inc. (US), Gotham Therapeutics (US), Sumitomo Chemical Co., Ltd. (Japan), Eli Lilly and Company (US) Aldevron(U.S.), Beam Therapeutics (U.S.), CRISPR Medicine(U.S.), Genentech, Inc(U.S.)
Nucleic acid-based therapeutics comprise both DNA and RNA therapeutics which are further categorized into antisense oligonucleotides, enzymes, ribozymes, DNA aptamers, micro RNA, short interfering RNA, and RNA decoys. They are designed in such a way that can target the infected genes without causing any toxicity to other cells and tissues. These therapeutics also have the potential to prevent the expression of proteins. They are mainly used in the treatment of acquired immunodeficiency syndrome, cancer, diabetes, coronary heart diseases, neurodegenerative diseases, cystic fibrosis, hemophilia, and many other genetic disorders.
Global Nucleic Acid-Based Therapeutics Market Dynamics
- Increasing Prevalence of Genetic and Chronic Diseases
The rising incidence of genetic disorders, cancer, cardiovascular diseases, and other chronic conditions are driving the demand for nucleic acid-based therapeutics. These therapies have the potential to target specific disease-causing genes and provide personalized treatment options.
- Advances in Genomics and Molecular Biology
The rapid advancements in genomics, molecular biology, and gene editing technologies have paved the way for the development of nucleic acid-based therapeutics. Techniques such as CRISPR-Cas9 gene editing and RNA interference (RNAi) have expanded the possibilities for precise and targeted therapeutic interventions.
- Growing Investments in Research and Development
Governments, pharmaceutical companies, and biotechnology firms are increasing their investments in research and development activities focused on nucleic acid-based therapeutics. This financial support has fueled innovation and accelerated the development of new therapies in the market.
- Favourable Regulatory Environment
Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have established clear guidelines and accelerated pathways for the approval of nucleic acid-based therapeutics. These regulatory frameworks have encouraged companies to invest in the development of these therapies, driving market growth.
- Increasing Partnerships and Collaborations
Collaboration between pharmaceutical companies, biotechnology firms, and academic institutions has become more prevalent in the nucleic acid-based therapeutics market. Partnerships facilitate knowledge sharing, resource pooling, and technological advancements, leading to faster product development and commercialization.
- Rising Demand for Personalized Medicine
Nucleic acid-based therapeutics offer the potential for personalized medicine by targeting specific genetic mutations or variations. With the increasing focus on personalized healthcare, these therapies are gaining significant attention and acting as an opportunity for market growth
- High Development Costs
The development and commercialization of nucleic acid-based therapeutics involve extensive research, clinical trials, and regulatory processes. These activities require substantial investments, which can be a significant restraint for smaller companies and startups, limiting their participation in the market.
Efficient delivery of nucleic acid-based therapeutics to target cells or tissues remains a challenge. The nucleic acids are often large and negatively charged molecules that can be easily degraded or cleared by the body's immune system before reaching the intended site. Developing effective delivery systems that ensure targeted and safe delivery is crucial for the success of these therapies.
This Nucleic acid-based therapeutics Market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Nucleic acid-based therapeutics Market Contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
- In December 2022, li Lilly and Company (NYSE: LLY) and ProQR Therapeutics N.V. (Nasdaq: PRQR), today announced the expansion of their licensing and collaboration agreement to Expand RNA Editing Collaboration
- In November 2020, Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced the accomplished Ionis scientists will highlight the company's pioneering advancements in research and drug development in antisense technology during the RNA at the Bench and Bedside II Conference,
Global Nucleic Acid-Based Therapeutics Market Scope
The nucleic acid-based therapeutics market is segmented on the basis of applications, structure, technologies, end-users, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Monogenic Disorders
- Multigenic Disorders
- Single Stranded RNA/DNA
- Double Stranded DNA
- Anti-Sense Technology
- Gene Therapy
- RNA and DNA Therapy
- Nucleoside Analogs
- Research Institutes
Global Nucleic Acid-Based Therapeutics Market Regional Analysis/Insights
The nucleic acid-based therapeutics market is analysed and market size insights and trends are provided by country, applications, structure, technologies, end-users, and distribution channel as referenced above.
The countries covered in the nucleic acid-based therapeutics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to dominate the nucleic acid-based therapeutics market because of the strong base of healthcare facilities, strong presence of major players in the market, the increasing prevalence of genetic and chronic diseases, and rising number of research activities in this region.
Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote awareness, rise in medical tourism, growing research activities in the region, availability of massive untapped markets, large population pool, and the growing demand for quality healthcare in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The nucleic acid-based therapeutics market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kind of products for nucleic acid-based therapeutics market, impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the nucleic acid-based therapeutics market. The data is available for the historic period 2010-2020.
Competitive Landscape and Global Nucleic Acid-Based Therapeutics Market Share Analysis
The nucleic acid-based therapeutics market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the nucleic acid-based therapeutics market.
Some of the major players operating in the nucleic acid-based therapeutics market are:
- Eli Lilly and Company (U.S.)
- Wave Life Sciences Ltd. (U.S.)
- Copernicus Therapeutics Inc. (U.S.)
- Imugene (Australia)
- PYC Therapeutics (Australia)
- Protagonist Therapeutics Inc. (U.S.)
- Benitec Biopharma (Australia)
- Egen, Inc. (U.S.)
- Biomedica Medizinprodukte GmbH (UK)
- Transgene (France)
- Arrowhead Pharmaceuticals, Inc. (U.S.)
- Ionis Pharmaceuticals (U.S.)
- Alnylam Pharmaceuticals, Inc. (U.S.)
- Moderna, Inc. (U.S.)
- Gotham Therapeutics (U.S.)
- Sumitomo Chemical Co., Ltd. (Japan)
- Beam Therapeutics (U.S.)
- CRISPR Medicine(U.S.)
- Genentech, Inc(U.S.)